Powered by lexis nexis

Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies

Mar 22, 2017 - PR Newswire

Expects Phase I Results in the Third Quarter of 2017

Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill(TM) platform technology, announces the initiation of a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with the two primary cannabinoids contained inCannabis sativa,cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed by Intec for various indications...